Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (Protocol 008)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The purpose of this study is to evaluate the safety of two doses (6 Development Units \[DU\] and 12 DU) of MK-8237 sublingual tablets compared to Placebo in adolescents with house dust mite-induced allergic rhinitis/rhinoconjunctivitis. The primary hypothesis is that at least one dose of MK-8237 sublingual tablet is safe and well-tolerated in adolescents with house dust mite-induced allergic rhinitis/rhinoconjunctivitis.
Epistemonikos ID: 353812305ee703e680ba7873d82d6ed7508de1b0
First added on: May 11, 2024